Schaeffers Research
08 Jun 2026, 13:45 UTC · 21w ago
Nurix Therapeutics Stock Pops on Roche Partnership
Impact · against what's priced in
NRIX is a strong buy following a massive de-risking event through the Roche partnership, which provides $700 million in immediate non-dilutive capital and validates the bexobrutideg program. RHHBY sees negligible impact as the deal is a standard strategic acquisition of a late-stage asset for a company of its scale.
- NRIX+0.90
No priced-in read yet
- In context
The $700 million upfront payment and potential $1.6 billion in milestones provide massive capital and validation for bexobrutideg, while the move to Phase 3 trials significantly advances the drug's commercial path.
Read from the article alone
Search tags
